Overdiagnostik en uundgåelig konsekvens af medicinsk screening



Relaterede dokumenter
Definisjoner og dilemmaer

Overdiagnostik & screening

Hvor mange har egentlig kræft?

PSA & CRC screening Siffer og skjebne. Beslutninger under usikkerhet

I den gode sags tjeneste - når forebyggelse gør mere skade end gavn

Evidence and ethics: dilemmas of medical prevention

Screening for tarmkræft: FOBT og sigmoideoskopi

Sport for the elderly

Brystkræftscreening og overdiagnostik hvordan forstår vi stigningen i incidens?

applies equally to HRT and tibolone this should be made clear by replacing HRT with HRT or tibolone in the tibolone SmPC.

Nye resultater fra det danske screeningsprojekt

X M Y. What is mediation? Mediation analysis an introduction. Definition

Kun 10 % er i alkoholbehandling hvordan får vi flere i alkoholbehandling?

Patientinvolvering & Patientsikkerhed er der en sammenhæng? #patient16

Demensdagene 7. maj Nis Peter Nissen Alzheimerforeningen

Kreftscreening generelt

Basic statistics for experimental medical researchers

Modtageklasser i Tønder Kommune

Fysiske arbejdskrav og fitness

Øjnene, der ser. - sanseintegration eller ADHD. Professionshøjskolen UCC, Psykomotorikuddannelsen

Skal kræftdiagnosen stilles hurtigt og tidligt? Og hvordan så?

Ovl. Hans Mørch Jensen Prof. L. V. Kessing. Prof. Ø. Lidegaard Prof. P. K. Andersen PhD, MD, L. H. Pedersen Biostatistiker Randi Grøn

LESSON NOTES Extensive Reading in Danish for Intermediate Learners #8 How to Interview

Bilag. Resume. Side 1 af 12

DBCG s 30års jubilæums møde. Mammografiscreening i DK Før, nu og i fremtiden. Ilse Vejborg Mammografiscreeningen i Region Hovedstaden

Morten Rasmusen Overlæge Ph.-D Abdominalcenter K Bispebjerg Hospital Chef for tarmkræftscreening i Region Hovedstaden

Privat-, statslig- eller regional institution m.v. Andet Added Bekaempelsesudfoerende: string No Label: Bekæmpelsesudførende

CT doser og risiko for kræft ved gentagende CT undersøgelser

Hvordan går det danske patienter med testis cancer?

Financial Literacy among 5-7 years old children

Alfa-1-antitrysin mangel hos børn. Elisabeth Stenbøg, Afd.læge, PhD Børneafd. A, AUH

Agenda. The need to embrace our complex health care system and learning to do so. Christian von Plessen Contributors to healthcare services in Denmark

Vina Nguyen HSSP July 13, 2008

Project Step 7. Behavioral modeling of a dual ported register set. 1/8/ L11 Project Step 5 Copyright Joanne DeGroat, ECE, OSU 1

Danish Language Course for International University Students Copenhagen, 12 July 1 August Application form

Trolling Master Bornholm 2016 Nyhedsbrev nr. 8

NOTIFICATION. - An expression of care

Status -virker rehabilitering efter kræft

Patientinddragelse i forskning. Lars Henrik Jensen Overlæge, ph.d., lektor

Statistik for MPH: 7

VELKOMMEN til Fagligt Symposium: Perspektiver på diagnostik og patientbehandling

Manuel behandling for patienter med hofteartrose

Danish Language Course for Foreign University Students Copenhagen, 13 July 2 August 2016 Advanced, medium and beginner s level.

Personale mangel 3 mulige løsninger

OBSERVERENDE UNDERSØGELSER. Kim Overvad Institut for Epidemiologi og Socialmedicin Aarhus Universitet Forår 2002

Trolling Master Bornholm 2015

Bedømmelse af klinisk retningslinje foretaget af Enhed for Sygeplejeforskning og Evidensbasering Titel (forfatter)

An expression of care Notification. Engelsk

Trolling Master Bornholm 2014

Camilla van Deurs. Associate partner Arkitekt MAA PhD Lektor i Urban Design. Gehl Architects. Menneskevenlige byer er sunde byer!

Patienter som ikke direkte passer ind i et pakkeforløb Hvem er det, hvor mange og hvorfor ikke?

Remember the Ship, Additional Work

Diabetic Nephropathy

USERTEC USER PRACTICES, TECHNOLOGIES AND RESIDENTIAL ENERGY CONSUMPTION

Trolling Master Bornholm 2015

Laerdal Resuscitation User Network. Guideline 2015 og update om 10 steps to improve survival

Hvordan får vi bugt med det fedmefremmende samfund?

Danske erfaringer med hjemme-niv

Learnings from the implementation of Epic

Børneortopædi CP-hoften på 20 minutter

Engelsk G Opgaveark. Maj Dato Prøveafholdende institution Tilsynsførende

Titel: Barry s Bespoke Bakery

Tidlig palliativ indsats - overvejelser ift. klinik og forskning

Fejlbeskeder i SMDB. Business Rules Fejlbesked Kommentar. Validate Business Rules. Request- ValidateRequestRegist ration (Rules :1)

Traffic Safety In Public Transport

Barnets navn: Børnehave: Kommune: Barnets modersmål (kan være mere end et)

Arbejdspladsen. Hvorfor er arbejdspladsen int eressant som arena for forebyggelse?

Totally Integrated Automation. Totally Integrated Automation sætter standarden for produktivitet.

Engelsk. Niveau D. De Merkantile Erhvervsuddannelser September Casebaseret eksamen. og

INTEL INTRODUCTION TO TEACHING AND LEARNING AARHUS UNIVERSITET

Our Mission We have been in business for 19 years. We help people who have eye problems. Our custom tinted soft contact lenses change lives.

DK - Quick Text Translation. HEYYER Net Promoter System Magento extension

Engelsk. Niveau C. De Merkantile Erhvervsuddannelser September Casebaseret eksamen. og

Statistik for MPH: oktober Attributable risk, bestemmelse af stikprøvestørrelse (Silva: , )

Effekt på overlevelsen efter implementering af et CT-baseret opfølgningsprogram for lungecancer. Niels-Chr. G. Hansen

Vores mange brugere på musskema.dk er rigtig gode til at komme med kvalificerede ønsker og behov.

1 s01 - Jeg har generelt været tilfreds med praktikopholdet

Transkript:

Overdiagnostik en uundgåelig konsekvens af medicinsk screening John Brodersen Professor, speciallæge i almen medicin, ph.d. Center for Forskning & Uddannelse i Almen Medicin, IFSV, KU Forskningsenheden for Almen Praksis, Region Sjælland john.brodersen@sund.ku.dk

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 2

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 3

Traditionel medicin symptomer klinisk undersøgelse 4

Curative Medicine Help! 5

Moderne medicin symptomer klinisk undersøgelse mikroskopi/mikrobiologi/medikoteknologi/epidemiologi afvigelse/abnormitet/risikofaktor/patologi diagnose 6

Preventive Medicine I have something to offer you 7

Post-moderne medicin mikroskopi/mikrobiologi/medikoteknologi/epidemiologi afvigelse/abnormitet/risikofaktor/patologi korrekt diagnose + overdiagnostik illness 8

Post-moderne medicin mikroskopi/mikrobiologi/medikoteknologi/epidemiologi afvigelse/abnormitet/risikofaktor/patologi korrekt diagnose + overdiagnostik illness 9

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 10

Overdiagnostik - definition Overdiagnosis is the diagnosis of illnesses that would never have caused patients harm but potentially exposes them to treatments where the risks outweigh the benefits. Doust & Glasziou. Is the problem that everything is a diagnosis? Australian Family Physician 42:856-859, 2013. 11

Overdiagnostik - beskrivelse Overdiagnosis occur when individuals are diagnosed with conditions that will never cause symptoms or death the ultimate criterion for overdiagnosis: at the end of life, if the person never developed a problem from her condition, she has been overdiagnosed Welch, Schwartz, Woloshin. Overdiagnosed. Making People Sick in the Pursuit of Health, Boston: Beacon Press, 2011. 12

Overdiagnostik - min definition Diagnosticering af afvigelser, abnormiteter, risikofaktorer og/eller patologiske forandringer, som uopdaget eller udiagnosticeret aldrig i sig selv vil; give personen symptomer (eks. afvigelser), vil medføre sygelighed eller vil være årsag til personens død. 13

Overdiagnostik - 3 områder Nedsætte grænseværdier og/eller udvide sygdomsklassifikation Opfinde nye sygdomme (disease mongering) Overdetektion ved screening 14

Overdiagnostik - 3 områder Nedsætte grænseværdier og/eller udvide sygdomsklassifikation Opfinde nye sygdomme (disease mongering) Overdetektion ved screening 15

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 16

The Screening Cascade People who are screened Negative screening result Positive screening result Incidental finding Separate cascade Workup True positive False positive Indeterminate finding Surveillance Treatment Treatment works better early than later Benefit Rapidly progressive disease; person would die even if treated Mild, easily treatable disease; person would do well even if treated later Person would never have developed symptoms, even if untreated No Benefit Modified slide: Professor Russ Harris 17

Types of true positives The Screening Cascade People who are screened Negative screening result Positive screening result Incidental finding Separate cascade Workup True positive False positive Indeterminate finding Surveillance Treatment Treatment works better early than later Delayed Benefit Rapidly progressive disease; person would die even if treated Mild, easily treatable disease; person would do well even if treated later Person would never have developed symptoms, even if untreated No Benefit Modified slide: Professor Russ Harris 18

Types of true positives The Screening Cascade People who are screened Immediate harms/costs Negative screening result Positive screening result Incidental finding Separate cascade Workup True positive False positive Indeterminate finding Surveillance Treatment Treatment works better early than later Delayed Benefit Rapidly progressive disease; person would die even if treated Mild, easily treatable disease; person would do well even if treated later Person would never have developed symptoms, even if untreated No Benefit Modified slide: Professor Russ Harris 19

The Screening Cascade People who are screened Overdiagnosis Negative screening result Positive screening result Incidental finding Separate cascade Workup True positive False positive Indeterminate finding Surveillance Treatment Treatment works better early than later Delayed Benefit Rapidly progressive disease; person would die even if treated Mild, easily treatable disease; person would do well even if treated later Person would never have developed symptoms, even if untreated No Benefit Modified slide: Professor Russ Harris 20

Screening - på godt og ondt GODT Nedsat morbiditet og mortalitet Mere skånsom behandling Tryghed for ikke at være syg Primær forebyggende effekt ONDT Patienter i flere år Overdiagnostik Falsk tryghed Falsk alarm Overbehandling Øget morbiditet og mortalitet Induceret sygdom 21

Screening - på godt og ondt GODT Nedsat morbiditet og mortalitet Mere skånsom behandling Tryghed for ikke at være syg Primær forebyggende effekt ONDT Patienter i flere år Overdiagnostik Falsk tryghed Falsk alarm Overbehandling Øget morbiditet og mortalitet Induceret sygdom 22

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 23

Mammografiscreening 24

Lungecancerscreening m. CT-skanning 17.08.05 17.11.05 01.03.06 16.10.06 10.10.07 29.11.08 26.02.09 10.08.09 10.08.09 17.08.09 25

Natural History of Lung Cancer R. M. Lindell, T. E. Hartman, S. J. Swensen, J. R. Jett, D. E. Midthun, and J. N. Mandrekar. 5- year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest. 136 (6):1586-1595, 2009. 26

Heterogenitet i vækstrater ved AAA-screening Thompson et al. Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol.Assess. 17 (41):1-118, 2013. 27

Model: what happens at cancer screening? Cancer size Size at which cancer causes death Person A False negative screen from very fast growing cancer Persons B, C, D & E Screen-diagnosed cancer which would have progressed to symptoms and death Size at which cancer causes symptoms Size at which cancer can be detected Cancer diagnosis Cancer diagnosis Cancer diagnosis Cancer diagnosis Person F Overdiagnosed: Cancer would NOT have caused symptoms before death from other causes Person G No cancer diagnosis before death from other cause Death from other causes Death from other causes Abnormal cell Screening Test 1 Screening Test 2 Screening Test 3 Screening Test 4 Screening Test 5 Person H Overdiagnosed: Cancer spontaneously regressed before death from other cause Time Brodersen J., Schwartz L.M., Woloshin S. Overdiagnosis: How cancer screening can turn indolent pathology into illness. APMIS 122, 2014.

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 29

AAA screening: 38-44% ODx M. Johansson, A. Hansson, and J. Brodersen. Estimating overdiagnosis in screening for abdominal aortic aneurysm: could a change in smoking habits and lowered aortic diameter tip the balance of screening towards harm? BMJ 350:h825, 2015. 30

AAA screening: 38-44% ODx http://www.bmj.com/content/350/bmj.h825/infographic 31

Breast, mammography Lung, chest x-ray Lung, CT Liver, ultrasound Prostate, PSA Krag et al. Quantification of overdiagnosis in randomised trials of cancer screening: an overview of systematic reviews. POD conference 2015 32

Breast, mammography Lung, chest x-ray Lung, CT Liver, ultrasound Prostate, PSA Krag et al. Quantification of overdiagnosis in randomised trials of cancer screening: an overview of systematic reviews. POD conference 2015 33

Overdiagnostik (ODx) ved lungecancer CT screening NLST: 18,5% ODx Kontrolgruppen: Rtg. af thorax Mayo Lung Project: 51% ODx Best case: 18,5% ODx Worst case: 40,3% ODx 34

Danish lung cancer screening trial (DLCST): design Pedersen et al. The Danish Randomized Lung Cancer CT Screening Trial Overall Design and Results of the Prevalence Round. Journal of Thoracic Oncology 4 (5):608-614, 2009. 35

Hvor meget ODx i DLCST? 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Best case: 18,5% ODx Worst case: 40,3% ODx 36

Overdiagnosis in DLCST at 5 year follow-up 37

Overdiagnosis in DLCST at 5 year follow-up 96 68 24 53 38

Overdiagnosis in DLCST at 5 year follow-up 96 68 44 43 53 24 39

Overdiagnosis in DLCST at 5 year follow-up 96 68 44 43 53 24 40

Overdiagnostik i DLCST efter 5 års follow-up Extra antal af LC: 43 (96-53) ODx: 43/68=63% [95% CI;33%-88%] Wille MMW et al. Results of the randomized Danish Lung Cancer Screening Trial with focus on high-risk profiling. Accepted for publication August 2015 in AJRCCM 41

Styrker & svagheder Ingen screening i kontrolgruppen Lille kontaminering i kontrolgruppen Participation bias i DLCST? For kort follow-up? Ulige fordeling af storrygere efter randomiseringen? 42

Kardio-vaskulær risiko % 100 90 80 70 60 CVD diseases and number of risk factors 0 1 risk factor 2 risk factors 50 40 30 3 risk factors 20 10 0 20 25 30 35 40 45 50 55 60 65 70 75 Age CVD, diabetes and treated hypertension H. Petursson et al. Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? J.Eval.Clin.Pract. 15 (1):103-109, 2009. 43

Antal prøver Antal incidente cancer prostata PSA-test and Pca in DK 18000 16000 14000 500 450 400 12000 10000 8000 6000 4000 2000 350 300 250 200 150 100 50 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 0 Almen praksis er rekvirent Speciallæge/sygehus er rekvirent Incidente cancer prostatae T. O. Mukai, F. Bro, K. V. Pedersen, P. Vedsted. Brug af undersøgelse for prostataspecifikt antigen. Ugeskr.Laeger 172 (9):696-700, 2010. 44

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 45

A: Optimalt scenarium Esserman L., Shieh Y., & Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA: 302 (15):1685-1692, 2009. 46

B: Værste scenarium Esserman L., Shieh Y., & Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA: 302 (15):1685-1692, 2009. 47

C: Intermediært scenarium Esserman L., Shieh Y., & Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA: 302 (15):1685-1692, 2009. 48

Stadieskifte Esserman L., Shieh Y., & Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA: 302 (15):1685-1692, 2009. 49

Breast cancer screening Esserman L., Shieh Y., & Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA: 302 (15):1685-1692, 2009. 50

PSA-screening Esserman L., Shieh Y., & Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA: 302 (15):1685-1692, 2009. 51

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 52

Incidens og mortalitet Brodersen J., Schwartz L.M., Woloshin S. Overdiagnosis: How cancer screening can turn indolent pathology into illness. APMIS 122, 2014. 53

Cancer death and invasive cancer diagnosis with and without screening Lung, breast and prostate. France 1980-2010 Cases per year 60000 Death Lung Without screening Diagnosis Breast (women) Increasing screening Prostate Increasing screening 50000 40000 30000 20000 10000 2010 2005 2000 1995 1990 1985 1980 1995 1990 1985 1980 2010 2005 2000 1995 1990 1985 1980 2010 2005 2000 Years Years Years 54

Cancer death and invasive cancer diagnosis with and without screening Lung, breast and prostate. France 1980-2010 Cases per year 60000 Death Lung Without screening Diagnosis Breast (women) Increasing screening Prostate Increasing screening 50000 40000 30000 20000 10000 2010 2005 2000 1995 1990 1985 1980 1995 1990 1985 1980 2010 2005 2000 1995 1990 1985 1980 2010 2005 2000 Years Years Years 55

Cancer death and invasive cancer diagnosis with and without screening Lung, breast and prostate. France 1980-2010 Cases per year 60000 Death Lung Without screening Diagnosis Breast (women) Increasing screening Prostate Increasing screening 50000 40000 30000 20000 10000 2010 2005 2000 1995 1990 1985 1980 1995 1990 1985 1980 2010 2005 2000 1995 1990 1985 1980 2010 2005 2000 Years Years Years 56

Hvilke kræftsygdom er dette? 57

58

59

60

Screening med smartphone 61

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 62

Skadevirkning af overdiagnostik Overundersøgelse Overbehandling Overforbrug 63

Skadevirkning af overdiagnostik financial strain hassles/inconveniences medical costs opportunity costs physical harms psychological harms societal costs + work-related costs Harris R.P. et al. The Harms of Screening: A Proposed Taxonomy and Application to Lung Cancer Screening, JAMA 2014 64

Overdiagnostik v. screening Post-moderne medicin Definition Overdetektion ved screening Hvorfor? Eksempler Stadieskifte Incidens og mortalitet Konsekvenser af overdiagnostik Fremtiden? 65

Fremtiden? Storm P: Det er svært at spå især om fremtiden 66

Fremtiden? Mere screening: Befolkningsundersøgelser og højrisiko Quantified Self Big data & Personalised Medicine 67

Nye screeningsprogrammer? CT-screening for lungekræft blandt storrygere Abdominalt aorta anuerisme: Befolkningsundersøgelse eller storrygere? 68

Quantified Self 69

Big data & Personalised Medicine 70

P4 or Personalised medicine Predictive Preventive Personalised Participatory 71

P4 among healthy Predictive & Preventive = Screening Incognito 72

Big data & Personalised Medicine 73

Survivors stories drive screening towards more overdiagnosis More Intensive Screening More Useful Screening Appears To Be Popularity paradox More Overdiagnosis More Survivor Stories 74

75